Business Builders

“I Turned a $20M Company Into a $1.45 Billion Exit” | Cathal Friel, Raglan Capital

Conor Kearney Season 13 Episode 4

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 1:22:08

🔔🔔 Cathal Friel explains how he built five public companies, turned a $20 million business into a $1.45 billion exit, and why IPOs may be making a comeback for ambitious entrepreneurs 🔔🔔

Cathal Friel joins Business Builders for a fascinating conversation on entrepreneurship, IPOs, public markets, distressed assets, investing, AI, and building companies across multiple industries.

Cathal is a serial entrepreneur, investor, and company builder who has launched five public companies over the past fourteen years. His ventures have spanned sectors including oil and gas, pharmaceuticals, life sciences, renewable energy, and biotechnology.

But this conversation is about far more than stock markets and finance.

Cathal explains the repeatable model he has developed for identifying opportunities, acquiring distressed assets, raising capital, and building fast-growing public companies. He shares the story of how a struggling oil and gas company ultimately evolved into Amryt Pharma, which was later sold for $1.45 billion.

Drawing on decades of experience as both an entrepreneur and investor, Cathal breaks down the realities of IPOs, why many founders misunderstand public markets, and why he believes going public can be a powerful alternative to private equity.

Along the way, he reflects on being forced into the family business at sixteen, the lessons learned from rebuilding debt-ridden companies, the importance of rejection, networking, and continuous learning, and why entrepreneurship is a skill that can be developed rather than something people are simply born with.

The conversation also explores AI, the future of work, Europe’s economic outlook, leadership, parenting, and why Cathal remains as excited about building businesses at sixty-one as he was decades ago.

This is a conversation about entrepreneurship, reinvention, opportunity, resilience, and building businesses that create long-term value.


🎧 In this episode, you’ll learn 🎧:

• How Cathal built five public companies in fourteen years
 • The story behind a $1.45 billion pharmaceutical exit
 • Why IPOs are often misunderstood by entrepreneurs
 • The key differences between private equity and public markets
 • How distressed assets can become valuable businesses
 • Why investors care more about trust than ideas
 • The lessons Cathal learned from oil, pharma, biotech and renewables
 • How public companies can grow through acquisitions
 • Why rejection is a critical entrepreneurial skill
 • The importance of networking and building relationships
 • Why entrepreneurship is a learnable skill
 • The lessons Cathal learned from running his family business at sixteen
 • How to think about risk, opportunity and capital allocation
 • Why AI will reshape work and entrepreneurship
 • The future of IPOs in Ireland and the UK
 • Why continuous learning remains one of Cathal’s biggest advantages
 • The importance of balancing business success with family life
 • Why he believes Europe is entering a major period of opportunity


⏱️ Timestamps

00:00 - Cold open
 01:00 - Introducing Cathal Friel
 02:00 - Building companies through IPOs
 07:00 - How Cathal spots market opportunities
 12:00 - The story behind Amryt Pharma
 18:00 - Distressed assets and creating value
 24:00 - Why IPOs differ from private equity
 31:00 - Investing in small-cap companies
 37:00 - Building businesses through acquisitions
 44:00 - The future of public markets
 49:00 - Rejection, confidence and entrepreneurship
 58:00 - Running the family business at sixteen
 01:05:00 - Networking, business cards and relationships
 01:12:00 - AI, learning and the future of work
 01:21:00 - Europe, geopolitics and opportunity
 01:33:00 - Parenting, success and long-term thinking
 01:38:00 - Final reflections and advice


Topics covered:

Entrepreneurship, IPOs, investing, public companies, private equity, distressed assets, business growth, capital markets, pharmaceuticals, biotech, renewable energy, venture building, acquisitions, leadership, networking, AI, future of work, investing strategy, family business, business resilience, startup funding, innovation, company building, European business, entrepreneurship mindset, scaling businesses.